CN103037849A - 具有减少的食物效应的控释组合物 - Google Patents

具有减少的食物效应的控释组合物 Download PDF

Info

Publication number
CN103037849A
CN103037849A CN201180031366XA CN201180031366A CN103037849A CN 103037849 A CN103037849 A CN 103037849A CN 201180031366X A CN201180031366X A CN 201180031366XA CN 201180031366 A CN201180031366 A CN 201180031366A CN 103037849 A CN103037849 A CN 103037849A
Authority
CN
China
Prior art keywords
controlled release
pharmaceutical compositions
compositions according
release pharmaceutical
activating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180031366XA
Other languages
English (en)
Chinese (zh)
Inventor
陈守琼
李少明
詹秋明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TWI Pharmaceuticals Inc
Original Assignee
TWI Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TWI Pharmaceuticals Inc filed Critical TWI Pharmaceuticals Inc
Publication of CN103037849A publication Critical patent/CN103037849A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180031366XA 2010-06-22 2011-06-21 具有减少的食物效应的控释组合物 Pending CN103037849A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35725110P 2010-06-22 2010-06-22
US61/357,251 2010-06-22
PCT/US2011/041218 WO2011163206A2 (en) 2010-06-22 2011-06-21 Controlled release compositions with reduced food effect

Publications (1)

Publication Number Publication Date
CN103037849A true CN103037849A (zh) 2013-04-10

Family

ID=45328888

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180031366XA Pending CN103037849A (zh) 2010-06-22 2011-06-21 具有减少的食物效应的控释组合物

Country Status (13)

Country Link
US (1) US8486453B2 (enExample)
EP (1) EP2585052A4 (enExample)
JP (1) JP2013533241A (enExample)
KR (1) KR20140007247A (enExample)
CN (1) CN103037849A (enExample)
AR (1) AR084698A1 (enExample)
AU (1) AU2011271124A1 (enExample)
BR (1) BR112012032816A2 (enExample)
CA (1) CA2802335A1 (enExample)
MX (1) MX2012015188A (enExample)
RU (1) RU2012155890A (enExample)
TW (1) TW201206503A (enExample)
WO (1) WO2011163206A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103655570A (zh) * 2013-12-11 2014-03-26 深圳翰宇药业股份有限公司 西格列汀与二甲双胍复方缓释制剂及其制备方法
CN104739835A (zh) * 2013-12-30 2015-07-01 中美华世通生物医药科技（武汉）有限公司 一种治疗糖尿病的新型药物组合物
CN105055413A (zh) * 2015-07-23 2015-11-18 上海市第六人民医院 一种小檗碱和瑞格列奈的药物组合物
CN105287581A (zh) * 2014-07-15 2016-02-03 上海星泰医药科技有限公司 阿格列汀二甲双胍缓释片及其制备方法
WO2017114227A1 (zh) * 2015-12-30 2017-07-06 深圳翰宇药业股份有限公司 一种复方达格列净二甲双胍缓释片及其制备方法
CN107708681A (zh) * 2015-04-20 2018-02-16 安成生物科技股份有限公司 含有双醋瑞因的制剂及使用其降低尿酸血液水平的方法
CN116600791A (zh) * 2020-10-05 2023-08-15 泰拉克斯生物有限责任公司 药物制剂

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2395983B1 (en) 2009-02-13 2020-04-08 Boehringer Ingelheim International GmbH Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
US20130251795A1 (en) * 2010-07-30 2013-09-26 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AR085689A1 (es) * 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
PH12014500137A1 (en) 2011-07-15 2017-08-18 Boehringer Ingelheim Int Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
BR112014020186A8 (pt) * 2012-02-22 2017-07-11 Duchesnay Inc Formulação de doxilamina e piridoxina e/ou seus metabólitos ou sais
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting
WO2015010194A1 (en) 2013-07-22 2015-01-29 Duchesnay Inc. Composition for the management of nausea and vomiting
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
KR101633292B1 (ko) * 2014-02-25 2016-06-24 동아에스티 주식회사 용법이 개선된 엔테카비어를 함유하는 약학적 조성물
WO2015130083A1 (ko) * 2014-02-25 2015-09-03 동아에스티 주식회사 용법이 개선된 엔테카비어를 함유하는 약학적 조성물
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2015258859B2 (en) 2014-05-15 2020-07-23 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US9526703B2 (en) 2014-08-29 2016-12-27 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
CN105496970A (zh) * 2015-12-18 2016-04-20 北京华禧联合科技发展有限公司 含有利格列汀的组合物及其制备方法
WO2017153939A1 (en) * 2016-03-10 2017-09-14 Aurobindo Pharma Limited Pharmaceutical composition comprising canagliflozin, process of preparation and use thereof
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN119185557A (zh) 2018-04-06 2024-12-27 阿玛治疗公司 用于控释治疗剂的组合物
IT201800011119A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione cronotropica di sitagliptin
TR201916829A2 (tr) * 2019-10-31 2021-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari
CN110974792A (zh) * 2019-12-26 2020-04-10 南京亿华药业有限公司 一种结晶性药物片剂及其制备方法
KR20250154775A (ko) * 2024-04-22 2025-10-29 제이피바이오 주식회사 다파글리플로진, 리나글립틴 및 메트포르민을 포함하는 안정성이 향상된 약제학적 제제

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1283110A (zh) * 1997-12-23 2001-02-07 默克专利股份有限公司 用于立即和延长释放一种或多种活性物质的片剂
CN1308520A (zh) * 1998-03-20 2001-08-15 安得克斯制药公司 具有单一核心的控释口服片剂
CN1681496A (zh) * 2002-09-20 2005-10-12 安壮奇实验室公司 含有双胍和噻唑烷二酮衍生物的药物新剂型
CN1901880A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 用于增加二甲双胍吸收的组合物和剂型
US7214387B2 (en) * 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6360257B1 (en) * 1998-01-30 2002-03-19 Telefonaktiebolaget L M Ericsson (Publ) Managing group IP addresses in mobile end stations
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
PT1558220E (pt) * 2003-07-24 2010-03-12 Rasendrakumar Jha Composições orais para tratamento da diabetes
US20050163849A1 (en) * 2003-10-31 2005-07-28 Wong Patrick S. Compositions and dosage forms for enhanced absorption of iron
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1283110A (zh) * 1997-12-23 2001-02-07 默克专利股份有限公司 用于立即和延长释放一种或多种活性物质的片剂
CN1308520A (zh) * 1998-03-20 2001-08-15 安得克斯制药公司 具有单一核心的控释口服片剂
US7214387B2 (en) * 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin
CN1681496A (zh) * 2002-09-20 2005-10-12 安壮奇实验室公司 含有双胍和噻唑烷二酮衍生物的药物新剂型
CN1901880A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 用于增加二甲双胍吸收的组合物和剂型

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103655570A (zh) * 2013-12-11 2014-03-26 深圳翰宇药业股份有限公司 西格列汀与二甲双胍复方缓释制剂及其制备方法
CN104739835A (zh) * 2013-12-30 2015-07-01 中美华世通生物医药科技（武汉）有限公司 一种治疗糖尿病的新型药物组合物
CN105287581A (zh) * 2014-07-15 2016-02-03 上海星泰医药科技有限公司 阿格列汀二甲双胍缓释片及其制备方法
CN107708681A (zh) * 2015-04-20 2018-02-16 安成生物科技股份有限公司 含有双醋瑞因的制剂及使用其降低尿酸血液水平的方法
CN105055413A (zh) * 2015-07-23 2015-11-18 上海市第六人民医院 一种小檗碱和瑞格列奈的药物组合物
WO2017114227A1 (zh) * 2015-12-30 2017-07-06 深圳翰宇药业股份有限公司 一种复方达格列净二甲双胍缓释片及其制备方法
CN116600791A (zh) * 2020-10-05 2023-08-15 泰拉克斯生物有限责任公司 药物制剂

Also Published As

Publication number Publication date
TW201206503A (en) 2012-02-16
AR084698A1 (es) 2013-06-05
WO2011163206A3 (en) 2012-03-01
KR20140007247A (ko) 2014-01-17
US20110311594A1 (en) 2011-12-22
AU2011271124A1 (en) 2013-01-10
EP2585052A2 (en) 2013-05-01
CA2802335A1 (en) 2011-12-29
WO2011163206A4 (en) 2012-04-26
BR112012032816A2 (pt) 2016-11-08
EP2585052A4 (en) 2014-10-01
US8486453B2 (en) 2013-07-16
WO2011163206A2 (en) 2011-12-29
MX2012015188A (es) 2013-05-20
RU2012155890A (ru) 2014-07-27
JP2013533241A (ja) 2013-08-22

Similar Documents

Publication Publication Date Title
CN103037849A (zh) 具有减少的食物效应的控释组合物
KR100762847B1 (ko) 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
US8911781B2 (en) Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US20100330177A1 (en) Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
JP2011513408A (ja) メトホルミン及びジペプチジルペプチダーゼ−ｉｖ阻害剤の併用医薬組成物
CN114929210A (zh) 抗糖尿病药物组合物和其制备方法
US20150283248A1 (en) Pharmaceutical compositions of Linagliptin and process for preparation thereof
KR101409330B1 (ko) 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
KR102696669B1 (ko) 벤즈이미다졸 유도체 화합물을 포함하는 약학적 조성물
US20150366863A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
EP3731828A2 (en) Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
EP3784672A2 (en) Tablet formulations comprising metformin and sitagliptin
US20150374688A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof.
CN105769796A (zh) 一种含有维格列汀和盐酸二甲双胍的药物制剂及其制备方法
WO2020046243A2 (en) Extended release osmotic tablet dosage form comprising metformin and sitagliptin
WO2025116860A1 (en) A tablet comprising an extended-release formulation for metformin and immediate release formulation comprising sitagliptin
EP4566593A1 (en) A tablet comprising an extended-release formulation for metformin and immediate release formulation comprising sitagliptin
EP4212150A1 (en) A bilayer tablet composition comprising amorphous dapagliflozin and metformin
TR2023002813A1 (tr) Si̇tagli̇pti̇n veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzunu i̇çeren bi̇r fi̇lm kapli tablet
WO2006077494A2 (en) A process for preparing solid dosage forms for extended-release of biguanide and sulfonylurea

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130410